Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?
- 1 August 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (7) , 480-492
Abstract
Minimal residual disease (MRD), or isolated tumor cells (ITCs) in bone marrow, may be the source of potentially fatal overt distant metastases in solid tumors even years after primary treatment. MRD can be detected by immunohistochemical methods using antibodies directed against cytokeratins or cell-surface markers or molecular, polymerase chain reaction–based techniques. Among solid tumors, the clinical relevance of MRD has been most extensively studied in breast cancer patients. Recently, the highest level of evidence for the prognostic impact of MRD in primary breast cancer was reached by a pooled analysis comprising more than 4,000 patients, showing poor outcome in patients with MRD at primary therapy. Yet the clinical application of MRD detection is hampered by the lack of a standardized detection assay. Moreover, clinical trial results demonstrating the benefit of a therapeutic intervention determined by bone marrow status are still absent. Recent results suggest that, in addition to its prognostic impact, MRD can be used for therapy monitoring or as a potential therapeutic target after phenotyping of the tumor cells. Persistent MRD after primary treatment may lead to an indication for extended adjuvant therapy. However, until clinically relevant data regarding successful therapy of MRD are available, treatment interventions on the basis of MRD should only be performed within clinical trials.Keywords
Funding Information
- German Research Foundation (DFG BR2149/1)
This publication has 121 references indexed in Scilit:
- The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrenceCancer, 2005
- Dissecting the metastatic cascadeNature Reviews Cancer, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Genetic heterogeneity of single disseminated tumour cells in minimal residual cancerThe Lancet, 2002
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Classification of isolated tumor cells and micrometastasisCancer, 1999
- Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up studyThe Lancet, 1999
- Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosisBreast Cancer Research and Treatment, 1997
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993